Gata2在急性早幼粒细胞白血病中的抑癌功能
该研究通过鉴定PML-RARA在小鼠和人类APL细胞中失调的基因,优先研究GATA2,因其在表达PML-RARA的白血病前细胞中高表达且持续至转化后APL细胞,并在疾病进展中出现体细胞突变。功能实验表明,Gata2双等位基因敲除增加PML-RARA表达髓系祖细胞的连续克隆形成能力、增加小鼠APL外显率并缩短潜伏期,而恢复Gata2表达可抑制异常自我更新和白血病发生,提示Gata2在AML中具有抑癌作用。
要点
- GATA2在PML-RARA表达的白血病前细胞中高表达并持续至APL细胞。
- Gata2敲除增强PML-RARA祖细胞连续克隆形成能力并加速小鼠APL。
- 恢复Gata2表达可抑制PML-RARA驱动的异常自我更新和白血病发生。
核心结论
- Gata2在AML中可能发挥抑癌功能,恢复其功能(当失活时)或可使AML患者获益。
研究设计与样本
- 研究鉴定了PML-RARA在小鼠和人类APL细胞中失调的基因,并优先对GATA2进行功能研究。
- 使用CRISPR/Cas9介导的基因编辑进行Gata2双等位基因敲除,并在小鼠APL模型中评估外显率和潜伏期。
- 通过恢复Gata2表达及回补突变型GATA2R362G蛋白进行功能验证。
主要发现
- GATA2在表达PML-RARA的白血病前细胞中高表达,其高表达在转化的APL细胞中持续存在。
- GATA2的体细胞突变在小鼠和人类APL进展过程中自发发生。
- Gata2双等位基因敲除增加了PML-RARA表达髓系祖细胞的连续克隆形成效率,也增加了表达RUNX1-RUNX1T1或Cebpa缺陷的祖细胞的连续克隆形成效率。
- Gata2敲除增加了小鼠APL外显率并缩短了潜伏期。
- 恢复Gata2表达抑制了PML-RARA驱动的异常自我更新和白血病发生;回补GATA2R362G突变蛋白仅轻微抑制异常自我更新,提示该突变为功能丧失性突变。
关键数值与推荐
- Gata2双等位基因敲除增加PML-RARA表达髓系祖细胞的连续克隆形成效率。
- Gata2敲除增加小鼠APL外显率并缩短潜伏期。
- 恢复Gata2表达抑制PML-RARA驱动的异常自我更新和白血病发生。
- 回补GATA2R362G突变蛋白对PML-RARA诱导的异常自我更新仅有轻微抑制作用。
临床怎么用
- 对于GATA2失活的AML患者,恢复GATA2功能可能是一种潜在治疗策略。
- GATA2突变状态可能有助于评估APL/AML疾病进展风险。
局限性
- 研究主要基于小鼠模型和体外实验, human临床验证尚需进一步研究。
- GATA2在APL中的抑癌机制及表观遗传沉默的具体作用未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most patients with acute promyelocytic leukemia (APL) can be cured with combined all-trans retinoic acid (ATRA) and arsenic trioxide therapy, which induces the destruction of PML-RARA, the initiating fusion protein for this disease. However, the underlying mechanisms by which PML-RARA initiates and maintains APL cells are still not clear. Therefore, we identified genes that are dysregulated by PML-RARA in mouse and human APL cells and prioritized GATA2 for functional studies because it is highly expressed in preleukemic cells expressing PML-RARA, its high expression persists in transformed APL cells, and spontaneous somatic mutations of GATA2 occur during APL progression in mice and humans. These and other findings suggested that GATA2 may be upregulated to thwart the proliferative signal generated by PML-RARA and that its inactivation by mutation (and/or epigenetic silencing) may accelerate disease progression in APL and other forms of acute myeloid leukemia (AML). Indeed, biallelic knockout of Gata2 with CRISPR/Cas9-mediated gene editing increased the serial replating efficiency of PML-RARA-expressing myeloid progenitors (as well as progenitors expressing RUNX1-RUNX1T1, or deficient for Cebpa), increased mouse APL penetrance, and decreased latency. Restoration of Gata2 expression suppressed PML-RARA-driven aberrant self-renewal and leukemogenesis. Conversely, addback of a mutant GATA2R362G protein associated with APL and AML minimally suppressed PML-RARA-induced aberrant self-renewal, suggesting that it is a loss-of-function mutation. These studies reveal a potential role for Gata2 as a tumor suppressor in AML and suggest that restoration of its function (when inactivated) may provide benefit for AML patients.
引用
- Katerndahl CDS, Rogers ORS, Day RB, et al. Tumor suppressor function of Gata2 in acute promyelocytic leukemia. Blood. 2021. PMID: 34125173. doi:10.1182/blood.2021011758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。